<SEC-DOCUMENT>0001104659-20-088088.txt : 20200730
<SEC-HEADER>0001104659-20-088088.hdr.sgml : 20200730
<ACCEPTANCE-DATETIME>20200730064532
ACCESSION NUMBER:		0001104659-20-088088
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200726
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200730
DATE AS OF CHANGE:		20200730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AdaptHealth Corp.
		CENTRAL INDEX KEY:			0001725255
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				823677704
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38399
		FILM NUMBER:		201059093

	BUSINESS ADDRESS:	
		STREET 1:		220 WEST GERMANTOWN PIKE
		STREET 2:		SUITE 250
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		610-630-6357

	MAIL ADDRESS:	
		STREET 1:		220 WEST GERMANTOWN PIKE
		STREET 2:		SUITE 250
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DFB Healthcare Acquisitions Corp.
		DATE OF NAME CHANGE:	20171213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2024607d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>AdaptHealth
Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact
name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of Earliest Event
Reported): July&nbsp;26, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 33%"><B>Delaware</B></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 32%"><B>001-38399</B></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 33%"><B>82-3677704</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>220 West Germantown Pike, Suite&nbsp;250<BR>
Plymouth Meeting, PA<BR>
</B><FONT STYLE="font-style: normal; font-weight: normal">(address of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>19462</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(zip code)<B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(610) 630-6357<BR>
</B>(Registrant&rsquo;s telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Check the appropriate box below if the
Form&nbsp;8-K is intended to</B> simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Written communication pursuant to Rule&nbsp;425 under the Securities Act (17 UR 230.425)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CPR 240.14a-12)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Pre-commencements communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">Securities registered pursuant
to Section&nbsp;12(b)&nbsp;of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 43%"><B>Title of each class</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 17%"><B>Trading Symbol(s)</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 38%"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class&nbsp;A Common Stock, par value $0.0001 per share</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>AHCO</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to that certain
Investment Agreement, dated as of May&nbsp;25, 2020 (the &ldquo;Investment Agreement&rdquo;), by and among AdaptHealth Corp., a
Delaware corporation (the &ldquo;Company&rdquo;), OEP AHCO Investment Holdings, LLC, a Delaware limited liability company (the
&ldquo;Purchaser&rdquo;), and, solely for purposes of Section&nbsp;3.10 thereof, One Equity Partners VII, L.P., a Delaware limited
partnership, the Company agreed to increase the size of its board of directors (the &ldquo;board&rdquo;) by two members in order
to elect to the board one individual designated by the Purchaser and one independent director nominated by the Company or the board.
As previously reported, on July&nbsp;9, 2020, the board voted to increase the size of the board by two members and appointed the
Purchaser&rsquo;s designee, Brad Coppens, to the board as a Class&nbsp;III director with a term expiring at the Company&rsquo;s
2022 annual meeting of stockholders to fill one of the newly-created vacancies. On July&nbsp;26, 2020, the board appointed David
S. Williams III to the board as a Class&nbsp;II director with a term expiring at the Company&rsquo;s 2021 annual meeting of stockholders
to fill the other vacancy. Mr.&nbsp;Williams will receive the same compensation opportunities as the Company&rsquo;s other non-employee
directors. The board has determined that Mr.&nbsp;Williams is &ldquo;independent&rdquo; within the meaning of the applicable rules&nbsp;and
regulations of the Securities and Exchange Commission and the listing standards of the Nasdaq Stock Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information
on the Investment Agreement, please refer to the description thereof under the heading &ldquo;Investment Agreement&rdquo; in Item
1.01 of the Company&rsquo;s Current Report on Form&nbsp;8-K filed with the Securities and Exchange Commission on May&nbsp;29, 2020
and the full text of the Investment Agreement, which is attached as Exhibit&nbsp;10.1 to such Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no other
arrangements or understandings between Mr.&nbsp;Williams and any other person pursuant to which Mr.&nbsp;Williams was selected
as a director. Mr.&nbsp;Williams has no direct or indirect material interest in any transaction required to be disclosed pursuant
to Item 404(a)&nbsp;of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July&nbsp;26, 2020,
the Company entered into an indemnification agreement with Mr.&nbsp;Williams in the form attached as Exhibit&nbsp;10.4 to the Company&rsquo;s
Current Report on Form&nbsp;8-K filed with the Securities and Exchange Commission on November&nbsp;14, 2019, which provides that,
subject to limited exceptions, and among other things, the Company will indemnify Mr.&nbsp;Williams to the fullest extent permitted
by law for claims arising in his capacity as a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July&nbsp;30, 2020,
the Company issued a press release announcing the appointment of Mr.&nbsp;Williams, <FONT STYLE="background-color: white">a copy
of which is filed as Exhibit&nbsp;99.1 hereto and incorporated herein by reference</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;<I>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><A HREF="tm2024607d2_ex99-1.htm">99.1</A></TD>
    <TD STYLE="width: 92%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><A HREF="tm2024607d2_ex99-1.htm">Press Release, dated July&nbsp;30, 2020</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">AdaptHealth Corp.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; width: 4%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 46%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">/s/ Gregg Holst</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Gregg Holst</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: July&nbsp;30, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2024607d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2024607d2_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FOR IMMEDIATE RELEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ADAPTHEALTH CORP. APPOINTS DAVID
S. WILLIAMS III</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TO BOARD OF
DIRECTORS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Plymouth Meeting, PA &ndash; July&nbsp;30,
2020 - AdaptHealth Corp. (NASDAQ: AHCO) (&ldquo;AdaptHealth&rdquo;), </B>a leading provider of home medical equipment, supplies
and related services in the United States, announced today the appointment of digital health executive and <FONT STYLE="background-color: white">innovator</FONT>
David S. Williams III to the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Williams
is co-founder of Care3,&nbsp;Inc. and currently serves as CEO. Founded in 2015, Care3 is </FONT>a next generation technology and
real-world data platform for patients, families, and medical and social care professionals to optimize care delivered in the home
and community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Prior
to Care3, Williams founded two digital health care companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In
2012, Williams co-founded and served as CEO of </FONT>InvolveCare, <FONT STYLE="background-color: white">a task crowdsourcing mobile
platform focused on family caregivers. </FONT>InvolveCare was funded and acquired by Aetna after 14 months of operation and served
as the base for the Aetna Medicaid mobile app. In 2006, Williams was the Founding Executive, Chief Marketing Officer and Head of
Business Development at PatientsLikeMe, which grew to become the world's leading online health data crowdsourcing platform and
was ultimately acquired by United Health Group in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Williams
began his career as an executive in the consulting and pharmaceutical industries, including Deloitte and Eli Lilly and Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">W<FONT STYLE="color: #111111">illiams
received his BS in Economics and Entrepreneurial Management from The Wharton School of the University of Pennsylvania and his MBA
in Digital Strategy from the UCLA Anderson School of Management. He is a member of the 2013 Class&nbsp;of Henry Crown Fellows with
The Aspen Institute and a member of the Aspen Global Leadership Network. Williams also serves on the board of directors of the
</FONT></FONT>Price Center for Entrepreneurship&nbsp;&amp; Innovation at UCLA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;David
is a tested, proven national healthcare executive and thought leader who has repeatedly helped bridge the communication and care
divide between patients, physicians and their families through the use of technology,&rdquo; said AdaptHealth CEO, Luke McGee.
&ldquo;We expect to benefit greatly from David&rsquo;s experience and insights as we continue to apply innovation, technology,
and best-in-class processes to further expand AdaptHealth&rsquo;s role as an integral part of the healthcare delivery ecosystem.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;It
is an honor to join the board of AdaptHealth at this exciting time in its development,&rdquo; said Mr.&nbsp;Williams. &ldquo;I
am impressed with the Company&rsquo;s entrepreneurial spirit, its commitment to innovation, and focus on patient care and satisfaction.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About AdaptHealth Corp.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AdaptHealth Corp. is a leading provider
of home healthcare equipment, medical supplies to the home and related services in the United States. AdaptHealth provides a full
suite of medical products and solutions designed to help patients manage chronic conditions in the home, adapt to life and thrive.
Product and services offerings include (i)&nbsp;sleep therapy equipment, supplies and related services (including CPAP and biPAP
services) to individuals suffering from obstructive sleep apnea, (ii)&nbsp;home medical equipment (HME) to patients discharged
from acute care and other facilities, (iii)&nbsp;oxygen and related chronic therapy services in the home, and (iv)&nbsp;other HME
medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy and nutritional
supply needs. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute
care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare,
Medicaid and commercial insurance payors. AdaptHealth services over approximately 1.7 million patients annually in all 50 states
through its network of 247 locations in 40 states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Forward Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes certain statements
that are not historical facts but are forward looking statements for purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as &ldquo;believe,&rdquo;
&ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;expect,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo;
&ldquo;seem,&rdquo; &ldquo;seek,&rdquo; &ldquo;future,&rdquo; &ldquo;outlook,&rdquo; and similar expressions that predict or indicate
future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not
limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections
of market opportunity and expectations, the Company&rsquo;s acquisition pipeline and the impact of the recent coronavirus (COVID-19)
pandemic and our response to it. These statements are based on various assumptions and on the current expectations of Company management
and are not predictions of actual performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are
provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a
guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are
difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the
control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including the
outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to
which the Company may become subject that could interrupt or limit the Company&rsquo;s operations, result in adverse
judgments, settlements or fines and create negative publicity; changes in the Company&rsquo;s clients&rsquo; preferences,
prospects and the competitive conditions prevailing in the healthcare sector; and the impact of the recent coronavirus
(COVID-19) pandemic and the Company&rsquo;s response to it. A further description of such risks and uncertainties can be
found in the Company&rsquo;s filings with the Securities and Exchange Commission. If the risks materialize or assumptions
prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There
may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could
also cause actual results to differ from those contained in the forward looking statements. In addition, forward-looking
statements reflect the Company&rsquo;s expectations, plans or forecasts of future events and views as of the date of this
press release. The Company anticipates that subsequent events and developments will cause the Company&rsquo;s assessments to
change. However, while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as
representing the Company&rsquo;s assessments as of any date subsequent to the date of this press release. Accordingly, undue
reliance should not be placed upon the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 30%"><FONT STYLE="background-color: #FEFEFE"><B>AdaptHealth Corp.</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 70%"><FONT STYLE="background-color: #FEFEFE"><B>The Equity Group Inc.</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Brittany Lett</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="background-color: #FEFEFE">Devin Sullivan</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Vice President, Marketing</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="background-color: #FEFEFE">Senior Vice
    President</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="background-color: #FEFEFE">(909)
    915-4983</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="background-color: #FEFEFE">(212) 836-9608</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><U>blett@adapthealth.com</U></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><U>dsullivan@equityny.com</U></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 30%">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 70%">Kalle Ahl, CFA</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Vice President</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="background-color: #FEFEFE">(212) 836-9614</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="background-color: #FEFEFE"><U>kahl@equityny.com
    </U></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2024607d2_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2024607d2_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  J 18# 2(  A$! Q$!_\0
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ME@L_'_C6VEO9=4DC69M$L5;RP\:-E3+(X<*S A1$_&2I'YF_LK?\$_?VRO\
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MD4 'B-XI#_"I)Q51RZ5ESSC%O9/?\M/F*6.5WR1<DMVOZU/U<HKYY_X)G?\
M!0CP]_P4@_9<L/'^E6PTC4;>9M.U[2FE\PZ7>QJK.H;C=&RLKHV!E6 .&# ?
M#]C^VA^U+_P6 _:'\:Z-^S?XET3X2_!SP%J']FS>*+NV6:[U9\L REDD)+!2
MZQQA-J,F]\LM9T\#4E*49VCR[M]"YXN"C&4?>YMK=3]9J\5_X*0HTG_!/KXV
MA9986_X0;6"LD;;70BRE((/8U^='[3%I^W=_P22\!Q_%6\^,^D?&WX?Z%<1#
M7M,U*S_>QQRRJ@9MR>:$+,B[XYMREQ\NW-?;WQ]^/^D_M4?\$>?'GQ%T-)(=
M+\8?#'4]2BAE(,EL7L)=\3$<%D?<A(XRIK3ZHZ<H5(R4HMVNN_;4CZRJBE3:
M::6S/+_^#;34)]3_ ."4OA*6YGFN)3J^J@O*Y=CB[?N:Z3_@CK_P4>\8?\%$
M-$^*5SXNT?PWI#^!O$0T>S&D13()H]KG=)YLCY;Y1R,#VKY3_P""4OP\_:)^
M(/\ P1X^%L?[//CSPCX%U.V\0ZVVLS:]9K<I=PFY(C5 ;>;!#!B>!U'-?/'_
M  1D^#'[77C32?BY'\$/BIX#\&1:=XI\CQ$FK6*SF^O<./-B)M)<)PW'R_2O
M2K8.G4=><I)/FZWTU>^G4X*6)G!48I.UOOT7Y'UQ_P %#@8_^#BW]D\AW&_1
M&!7=\O$FH]OQK]2J_%__ (+@?M#77[(G_!7/]G'Q_>:1<>*]4\+^$#*-/LSY
M;:E=M+>Q(BG:2%:5USA2<9P"<"O6(?V&O^"@'[4.B0^-?%'[1]E\)]8U)/M5
MMX1T6WDCMM*5@"D$S18&X=&R9B.?F;D5A7PJG1HSG-17+;7U?8VI8APJU(QB
MY._3T7<_4BBORS_X)Q?\%7/BC\(?VD_B!^S]^U?=63^*/ ]I]NL_$D4*(;Q-
M\(5&\M5619(YXY8Y BMM#!QG !7G5L#5IRY;7\ULSMI8NG4CS7MY/<^D/'7_
M  4ETGQ7X*UC2E\-W4+ZE936H<WF=ADC9<X\OMGUKP7]FKXUV_P-^*:>(+FR
MDO8UCD3REDV'YE8=<'U]*^EOB%_P3M\$^%O .MZG;W_B)I].T^>ZC$D\)4LD
M;,,_N@<9'K7SG^RI\&]+^-7Q@CT'59;R&S:.5BULRK)E58CEE8=AVKZ3"O!^
MPG[)/EZ[G\[<04N)5FN$6/G%UF_W;7+9.ZWLDM[;IGUO\&?VBO#G[8&L7&C7
MGA>(Q:=";T?:W6X0$,J< J,'Y^OL:\P_:\^#ZZ;\5K&+P[X>$%A]@B:1;.UV
MQ%S)+DG QG 7/MBO=/@7^R=X=_9^UZ[U#1KK5IYKRW-NZW<D;*%+*V1M1><J
M*]0K\GX\X,R_B##RP]*U-MQ?/RIRTZ7>MOF?OG#$\THX./\ :S4JMW>UK6OI
MLDMO(XWP'\'O#&@V6F7]MX>TNTU"*"-Q,ELJ2*VT9.<9S4'[2WCSP1\+_@)X
MJ\0_$@:8W@;2-/DN=834+5;JWEA7^ Q,")"S;55,$LQ4 9(KN:^./^"^GPE\
M1?&;_@E7\3=,\,P7%Y?V4=GJLMK "TES;6UW%-, !R=L:-)COY=?293EV&P[
MA0HQ4(MJ]DEV5].IZ6(J25.4]VDS\SM:_P"#ANPT;XN^7^S9^RU\-="U.9FM
M=.O9=#675[V,\L!%8K$R[@.461^G4UY/_P %/?VDOVV?VG/V=(M2^-_@O5/!
M7PQL=5B;[,V@_P!C02WC"00Y68_:),#S,#)4=3S@UP?_  0__P""B?@K_@FW
M^U'J_BOQWX<U'6=+UK1)-)2[TV*.6]TMS+')O1)&4%6$>U@&!Y'7D'WC_@N'
M_P %S?"__!1+X+Z5\.?AGX>\16GARRU&/6M8U/6((XII6C5HXHDC1Y J;ILL
M[,"2$ '7/WRP_LL3&-*CI_,]?Z9\K[?VF'E*I5U_E6AS'_!#'7[WPM^R-^V[
MJ&G2-#>VGPQDDAD7[T;>1?<CW%><?\&\7A#3/&7_  5O^&$>J0Q7$=E_:-_
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M/^$LAX Q_P N45?K!3S3$588JI&$FEY/R09?1ISP\)2BF_3S&Q1+!$J(JHB
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M"FJZ/\/OA]HFCVNO6[6FJ23*U[<:E"V<Q32SEW>,Y/R$[>>E/^$O_!.OX)?
MG0/%^E^$/ASH&@:=X^LFT[7[>U601ZE;,LBF)@6.$Q+(,+C[U>TT4/$57=N3
MUWUW!4::LE%:>1QOP(_9^\&_LQ_#FW\)> M L_#7ARTEDFAL;4L8T>1BSM\Q
M)Y))ZUY5\8?^"3O[.?Q]^(E[XL\6?"7POJGB+4I/.O+T++;O=R=WD$3JKN>[
M,"3W)KZ'HHC7J1DYQDTWUN#I0<>5Q5CS?Q-^R%\-?&7Q@\*^/]3\(Z9>>,?!
M-LMGH>J/O\[385W[43#;<#S'Z@_>->D445#E)VN]BU%+9'B'QW_X)M_ O]IW
MX@2>*O'WPT\.>*?$,L$=L]]>H[2-'&"$7A@. ?2BO;Z*U6*K15E-V]69O#TF
&[N*^X__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
